Please ensure Javascript is enabled for purposes of website accessibility

Novartis to Manufacture Mass General's Coronavirus Vaccine Candidate

By Cory Renauer - May 28, 2020 at 2:26PM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

A subsidiary of the pharmaceutical giant will soon ramp up production of the nonprofit hospital's SARS-CoV-2 vaccine candidate, which has yet to enter human clinical trials.

Another one of the world's largest pharmaceutical companies is throwing its weight behind the development of a coronavirus vaccine. Novartis (NVS -0.65%) will partner with Massachusetts General Hospital to develop a SARS-CoV-2 vaccine candidate. 

An experienced partner

The Massachusetts Eye and Ear Institute, part of the nonprofit Mass General Brigham health system, has entered an agreement with AveXis, a gene-therapy developer that Novartis bought in 2018 for $8.7 billion, to mass-produce a vaccine candidate called AAVCOVID. It uses an adeno-associated viral (AAV) vector to deliver genetic blueprints that should spur the production of harmless protein fragments that resemble the spikes found on the surface of the coronavirus that causes COVID-19.

Laboratory employees in full hazard gear.

Image source: Getty Images.

AveXis is probably a good fit to handle the production of AAVCOVID: The Novartis subsidiary already manufactures Zolgensma, one of just two AAV-based gene therapies currently approved by the FDA. Swiss pharmaceutical giant Roche (RHHBY 0.60%) markets the other, Luxturna.

Scaling up

While it's true that Novartis has the means to produce an FDA-approved medicine based on AAV vector technology, that doesn't necessarily mean the company's ready to produce billions of doses of a new AAV vector vaccine at the moment. Zolgensma is a $2.1 million treatment for a rare, inherited, muscle-wasting disorder that affects roughly 30,000 children in the U.S. 

Though AAVCOVID is still in preclinical stage testing, Novartis is preparing to scale up production before trials with human subjects begin. AveXis will produce its first doses of AAVCOVID later this month. 

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Roche Holding AG Stock Quote
Roche Holding AG
$41.82 (0.60%) $0.25
Novartis AG Stock Quote
Novartis AG
$83.73 (-0.65%) $0.55

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns
S&P 500 Returns

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 07/06/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.